Pharmacogenomics

Aims & Scope

Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area.

Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field.

Pharmacogenomics focuses on those aspects that have the most direct relevance to the pharmaceutical industry and wider clinical community, including: -The emergence of new pharmacogenomic initiatives and their impact on R&D and regulatory strategies -Emerging technologies for accessing and exploiting genomic information -Reviews of genotyping and clinical data in particular therapeutic areas -Development of novel diagnostic products and strategies.

Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	1.9
2024	1.90

SJR (SCImago Journal Rank)

Year	Value
2024	0.516

Quartile

Year	Value
2024	Q3

h-index

Year	Value
2024	103

Journal Rank

Year	Value
2024	11274

Journal Citation Indicator

Year	Value
2024	533

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• PubMed
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance

  Citation: 767

  Authors: Frances J

• CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

  Citation: 607

  Authors: L DiAnne

• Solexa Ltd

  Citation: 588

  Authors: Simon

• High-Resolution DNA Melting Analysis for Simple and Efficient Molecular Diagnostics

  Citation: 542

  Authors: Gudrun H, Jana O, Carl T

• Analysis of the Adult Human Plasma Metabolome

  Citation: 434

  Authors: Kay A, Alvin, Matthew, K Eric, Anne M, Lining, Richard W, Satish C, John A, Michael V

• Carbamazepine, <i>HLA-B*1502</i> and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA Recommendations

  Citation: 357

  Authors: P Brent, Howard L

• HLA-B Locus in Japanese Patients with Anti-Epileptics and Allopurinol-Related Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

  Citation: 336

  Authors: Nahoko, Yoshiro, Michiko, Kayoko, Masahiro, Kouichi, Jun-ichi, Hirokazu, Yukitoshi, Masaaki, Shigeru, Masamichi, Hiroko, Mariko, Yixuan, Mayumi, Chie, Zenro, Ryuichi

• Metabolic Fingerprinting As A Diagnostic Tool

  Citation: 331

  Authors: David I, Warwick B, Julian L, J William, Royston

• Rationale and design of the LURIC study - a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease

  Citation: 293

  Authors: Bernhard R, Winfried, Bernhard O, Rainer, Jörg, Peter, Jochen

• Common Risk Allele in Aromatic Antiepileptic-Drug Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Han Chinese

  Citation: 256

  Authors: Shuen-Iu, Wen-Hung, Zhi-Sheng, Chien-Hsiun, Mo-Song, Rosaline Chung-yee, Chia-Yu, Yuan-Tsong

---